About Iconovo
Iconovo is a company based in Lund (Sweden) founded in 2013. Iconovo has raised $3.56 million across 4 funding rounds from investors including Gates Foundation and Vinnova. Iconovo operates in a competitive market with competitors including MannKind Corp, Impel NeuroPharma, Alexza, OptiNose and Qnovia, among others.
- Headquarter Lund, Sweden
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
$265.64 K (USD)-58.55as on Dec 31, 2024
-
Net Profit
-$3.73 M (USD)10.36as on Dec 31, 2024
-
EBITDA
-$2.76 M (USD)30.28as on Dec 31, 2024
-
Total Equity Funding
$3.56 M (USD)
in 4 rounds
-
Latest Funding Round
$883.8 K (USD), Grant
Jul 26, 2022
-
Investors
Gates Foundation
& 1 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Iconovo
Iconovo has successfully raised a total of $3.56M across 4 strategic funding rounds. The most recent funding activity was a Grant round of $883.8 thousand completed in July 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Iconovo
Iconovo has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include Gates Foundation and Vinnova.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital funding is provided to Swedish companies across sectors.
|
Locked | Locked | Locked | |
|
Charitable foundation investments on poverty reduction and healthcare
|
Locked | Locked | Locked |
Investor details for Iconovo
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Iconovo
Investment portfolio details for Iconovo
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Iconovo
Detailed financials for Iconovo
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Iconovo Comparisons
Peer comparison for Iconovo
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Iconovo
Iconovo operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as MannKind Corp, Impel NeuroPharma, Alexza, OptiNose and Qnovia, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of small-molecule drugs
|
|
| Locked | Locked | Locked |
Intranasal delivery technology for CNS diseases is developed.
|
|
| Locked | Locked | Locked |
Developer of products for the treatment of acute and intermittent conditions
|
|
| Locked | Locked | Locked |
Developer of smart devices for nasal drug delivery
|
|
| Locked | Locked | Locked |
Inhaled drug delivery devices are developed for pharmaceuticals.
|
|
| Locked | Locked | Locked |
Therapeutics for cardiopulmonary diseases are developed using inhaled therapies.
|
Detailed competitors of Iconovo
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Iconovo
Complete news archive for Iconovo
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Iconovo
Iconovo was founded in 2013.
Iconovo is headquartered in Lund, Sweden.
Iconovo is a funded company, having raised a total of $3.56M across 4 funding rounds to date.
Annual revenue of Iconovo is $265.64K as on Dec 31, 2024.
Iconovo was founded in 2013 as a medical device company based in Lund, Sweden. Inhalation devices are developed, focusing on dry powder inhalers such as ICOres for reservoir-based delivery, ICOcap for capsule-based use, ICOone as a unit-dose disposable option, and ICOpre with pre-metered doses sealed during manufacturing. Operations center on innovative drug delivery solutions within the healthcare sector.
Iconovo's top competitors include MannKind Corp, OptiNose and Impel NeuroPharma.
Iconovo has 2 investors. Key investors include Gates Foundation, and Vinnova.